Dietary Nitrate Acutely and Markedly Increased Exhaled Nitric Oxide in a Cystic Fibrosis Case

Conor P. Kerley, BSc; Emma Kilbride, BSc; Peter Greally, MD; and Basil Elnazir, MD

Running title: Dietary nitrate increases exhaled nitric oxide

Tables: 3
Figures: 1
Abstract word count: 88
Main text word count: 1,129

Institution at which the work was performed: Paediatric Respiratory Department, National Children's Hospital, Dublin 24, Ireland.

Conflicts of interest: none

Corresponding Author: Conor P. Kerley, BSc
Paediatric Respiratory Department
National Children’s Hospital
Tallaght, Dublin 24
IRELAND
Email: conorkerley@gmail.com

Financial support: Financial support for this project was provided by the Foundation of National Children’s Hospital. The sponsor had no involvement in study design, data collection, analysis or interpretation, or manuscript preparation.

Copyright ©2016 Marshfield Clinic Health System

Copyright 2016 by Marshfield Clinic.
Abstract

Airway nitric oxide (NO) is a ubiquitous signaling molecule with bronchoprotective, anti-inflammatory and anti-infective roles. Cystic fibrosis (CF) is a chronic lung condition associated with deceased exhaled NO. Strategies to increase exhaled NO in CF have yielded inconsistent results. A potential new method of increasing systemic NO involves ingestion of dietary, inorganic nitrate which is reduced to nitrite and NO. We present the case of a 12 year-old, athletic male with CF who demonstrated acute but marked increases in exhaled NO following dietary nitrate consumption compared to placebo.

Keywords: Cystic fibrosis; Dietary nitrate; Nitrite; Exhaled nitric oxide
**Introduction**

Nitric oxide (NO) is a ubiquitous signaling molecule with multiple systemic and airway roles. Cystic fibrosis (CF) is a chronic lung condition which is associated with decreased fraction of exhaled NO (FeNO)\(^1\)-\(^4\).

The impact of decreased FeNO in CF is unclear. However, potentially of relevance to CF, NO has bronchoprotective, anti-inflammatory and anti-infective roles as well as effects on ion transport\(^5\) and ciliary motility\(^6\). Interestingly, pulmonary function in CF subjects is positively correlated to airway NO\(^7\) and sputum NO metabolites\(^8\). Further, NO deficiency contributes to impairment of airway relaxation in a murine model of CF\(^1\). Therefore, increasing NO levels may be of functional importance in CF. Strategies to increase FeNO in CF have included inhaled NO, L-arginine and PDE5 inhibitors (e.g. sildenafil \(^8\)) but have yielded inconsistent safety and efficacy profiles (table 3).

Until recently, it was thought that the only pathway for NO synthesis *in vivo* was via oxidation of L-arginine in the presence of oxygen catalysed by NO synthase (NOS) enzymes. However recently an alternative pathway for *in vivo* NO synthesis has been discovered whereby inorganic nitrate is reduced by oral bacteria to nitrite. This nitrite can be further reduced to NO enzymatically and non-enzymatically\(^9\). Dietary nitrate is now recognized as an additional and very significant source of NO, whereby a single serving of a nitrate rich vegetables (e.g. spinach) contains more nitrate than what is endogenously formed by the all three NOS isoforms combined in 24h\(^9\). Recent human intervention trials have demonstrated hypotensive and ergonomic effects
of dietary nitrate in conjunction with increased blood NO metabolites among multiple healthy and clinical groups.

**Case report**

We present a 12 year-old, non-smoking, athletic, male (BMI = 19 kg/m$^2$) with CF, normal lung function (FEV$_1$ = 105%) and pancreatic sufficiency. This case initially presented early in life with a history of recurrent chest infections and wheezy episodes. An initial sweat test chloride of 112 and confirmatory sweat test chloride of 106 in addition to genotype analysis (F508/c.262_263delTT) lead to a CF diagnosis at 9 months of age. Current investigations revealed a normal x-ray, DEXA, and glucose tolerance test with no recent hospital admissions or gastrointestinal symptoms. Further, the case had no other medical history of note, including no asthma or allergy (which could influence FeNO measurement). He generally requires antibiotics every 8-12 weeks but had no recent infection or antibiotic use and had no evidence of concurrent bacterial colonization. Further his medication regimen was stable and typical for a CF case (table 1). We utilized a double-blind, randomized, placebo-controlled, crossover design to assess the acute impact of dietary nitrate as 140ml beetroot juice (BRJ, 12.9mmol nitrate) or 140ml matched, nitrate-depleted beetroot juice (PL, <0.5mmol) on exhaled NO. This nitrate dose is obtainable with a diet rich in vegetables.

We conducted two clinic visits 14 days apart, where there were no relevant changes in factors known to influence NO (including diet, exercise and medication habits). On the morning of each study visit, the subject did not use any medications or complete chest physio and consumed an identical, low nitrate breakfast which was confirmed by a review with a dietitian (CPK). On both
days, in an identical manner and at the same time, FeNO (NiOx MINO; Aerocrine, Sweden) and pulmonary function were assessed before and 1.5h after the study beverage. We added water and blackcurrant cordial (sugar- and nitrate-free) to the juice in an identical manner on both days to make it more palatable at the request of the subject. The 1.5h delay between baseline and post-beverage testing was to facilitate in-vivo reduction of dietary nitrate to NO\textsuperscript{9}. During this delay, the case rested quietly in a clinic room and did not exercise, eat, drink or take medication. This case report intervention complies with the Declaration of Helsinki and approval was granted by the research ethics committee of The National Children’s Hospital. Written informed consent was provided by the mother for permission to conduct and publish this case report.

There was no effect on pulmonary function after either beverage. However, 1.5h following BRJ, FeNO increased by 150% (30ppb) but decreased by 17% after PL (-4ppb) (figure 1 and table 2).

**Discussion**

To our knowledge, this is the first report of dietary nitrate in CF. The acute but marked FeNO increase following dietary nitrate compares favourably to other NO therapies in CF (table 3). Interestingly, the subject studied here did not have low baseline FeNO (20ppb). Dietary nitrate as a precursor to NO seems most effective in those with dysregulated NO and therefore it is possible that dietary nitrate may increase FeNO to a similar or greater extent in those with diminished baseline FeNO. Despite an increase in FeNO, there was no effect on lung function. In this context, it is noteworthy that baseline lung function was not impaired (105%), perhaps minimising any potential benefit.
Dietary nitrate is water soluble and rapidly absorbed ~100% in the stomach and small intestine. There is no evidence of nitrate malabsorption in CF. Approximately 75% of ingested nitrate is excreted via the kidneys with the remainder concentrated in the oral gland and subsequently reduced to nitrite by tongue anaerobes. This nitrite is swallowed and then further reduced to NO under suitable conditions within the airway, stomach and endothelium. After nitrate ingestion, salivary/plasma nitrate levels increase rapidly (~15m) and peaking at 90-120m. The levels remain high for several hours following ingestion after which they slowly decline, remaining elevated from baseline for ~24h. This is why we measured FeNO before and 1.5h after each of 2 beverages. Further, we measured total exhaled NO. Future studies may utilize different doses of nitrate among larger groups as well employ serial measurements of NO, nitrate and nitrite to further our understanding of NO metabolism in response to exogenous nitrate in CF.

Importantly, this CF case did not display several behaviors known to decrease the reduction of dietary nitrate to NO including use of tobacco, antibiotics or mouthwash. Although, our report is limited to a single male, CF case with mild disease, dietary nitrate is a component of certain vegetables, appears remarkably safe and increased FeNO to a greater extent than existing CF therapies.

Nitrate and nitrate, as precursors to NO, are known to have broad antimicrobial effects, including against common pathogens in CF such as Pseudomonas aeruginosa and Staphylococcus aureus. Further, this antimicrobial activity has been demonstrated under cystic fibrosis airway conditions.
We recommend that future studies measuring FeNO are aware of potential confounding by dietary intake. Further the dietetic focus regarding CF typically emphasizes dietary fat with little focus on vegetable intake. We suggest the dietary modification of FeNO, including via vegetable consumption in CF is worthy of further exploration. We suggest the dietary modification of FeNO, including via vegetable consumption in CF is worthy of further exploration.

**Author Affiliations:**

Conor P. Kerley, BSc\(^1, 2\); Emma Kilbride, BSc\(^1\); Peter Greally, MD\(^1\); Basil Elnazir, MD\(^1\)

\(^1\)Paediatric Respiratory Department, National Children's Hospital, Dublin 24, Ireland

\(^2\)School of Medicine and Medical Sciences, University College Dublin, Belfield, Dublin 4, Ireland
References


Table 1: Current medication regimen

<table>
<thead>
<tr>
<th>Category</th>
<th>Medication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bronchodilators</td>
<td>Ventolin</td>
</tr>
<tr>
<td></td>
<td>Flixotide</td>
</tr>
<tr>
<td>PERT</td>
<td>Creon</td>
</tr>
<tr>
<td>Airway clearance aid</td>
<td>Nebulized pulmozyme</td>
</tr>
<tr>
<td>Nutritional supplements</td>
<td>Vitamin D</td>
</tr>
<tr>
<td></td>
<td>Aquadex</td>
</tr>
<tr>
<td></td>
<td>Probiotics</td>
</tr>
<tr>
<td>Chest physio</td>
<td>Twice daily with acapella® device.</td>
</tr>
</tbody>
</table>

PERT = pancreatic enzyme replacement therapy.
Table 2: Pulmonary function tests

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Day 1</th>
<th>Day 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FeNO (ppb)</td>
<td>20</td>
<td>24</td>
</tr>
<tr>
<td>FVC L (%)</td>
<td>3.66 (106)</td>
<td>3.63 (105)</td>
</tr>
<tr>
<td>FEV₁ L (%)</td>
<td>3.07 (107)</td>
<td>3.03 (105)</td>
</tr>
<tr>
<td>Post beverage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FeNO (ppb)</td>
<td>50</td>
<td>20</td>
</tr>
<tr>
<td>FVC L (%)</td>
<td>3.67 (106)</td>
<td>3.52 (101)</td>
</tr>
<tr>
<td>FEV₁ L (%)</td>
<td>3.06 (106)</td>
<td>2.9 (101)</td>
</tr>
</tbody>
</table>

Abbreviations:
BRJ = nitrate-rich neetroot juice; FeNO = fraction exhaled nitric oxide; FEV₁ = forced expiratory volume; FVC = forced vital capacity; ppb = parts per billion; PL = placebo - nitrate-depleted beetroot juice.
Table 3: Comparison of FeNO response to oral nitrate and L-arginine in CF

<table>
<thead>
<tr>
<th>Sample</th>
<th>Intervention</th>
<th>Intervention period</th>
<th>Baseline FeNO</th>
<th>End FeNO</th>
<th>Effect on FeNO</th>
<th>Comment</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 children with (3 male, aged 6-16y)</td>
<td>Oral L-arginine at a dose of 150 mg/kg/day</td>
<td>4 weeks</td>
<td>Not reported</td>
<td>Not reported</td>
<td>No significant impact on FeNO</td>
<td>Plasma L-arginine increased</td>
<td>Everard &amp; Donnelly 2005²</td>
</tr>
<tr>
<td>8 subjects (3 male, aged range 14–37y)</td>
<td>Oral L-arginine at a dose of 200 mg/kg</td>
<td>Acute</td>
<td>5.4±2.1ppb</td>
<td>Increased to 6.5ppb at 1h (p=0.06) and 9.2ppb at 3h (p=0.02)</td>
<td>Increased by 1.1ppb (+20%) at 1h and by 3.8ppb (+70%) at 3h</td>
<td>Significant increases in plasma arginine and products of L-arginine metabolism by arginase (ornithine and urea) but not citrulline (the product of L-arginine conversion by NOS)</td>
<td>Grasemann et al 2005³</td>
</tr>
<tr>
<td>11 subjects (6 male, aged 15-41y) after 2 weeks of antibiotic therapy</td>
<td>Oral L-arginine (600 mg/kg/day) followed by placebo or vice versa</td>
<td>6 weeks</td>
<td>11.4±6ppb</td>
<td>9.7ppb</td>
<td>Decreased by 1.7ppb (-18%)</td>
<td>FeNO decreased after 6w placebo by 6.3ppb which was significantly lower than FeNO at baseline (p=0.001) and after L-arginine (p=0.003)</td>
<td>Grasemann et al 2005³</td>
</tr>
<tr>
<td>15 CF cases</td>
<td>Ivacaftor</td>
<td>4 weeks</td>
<td>8.5±5.0</td>
<td>16.2±15.5ppb</td>
<td>Increased by 7.7ppb (+90%)</td>
<td>-</td>
<td>Grasemann et al 2015⁴</td>
</tr>
<tr>
<td>A single case (male, aged 12)</td>
<td>Dietary nitrate (12.9mmol) vs. placebo (0.5mmol)</td>
<td>Acute</td>
<td>20ppb</td>
<td>50ppb</td>
<td>Increased by 30ppb (+150%)</td>
<td>FeNO decreased after PL (-4ppb, 17%)</td>
<td>Current case report</td>
</tr>
</tbody>
</table>

Abbreviations: FeNO = fraction of exhaled nitric oxide; PL = placebo; ppb = parts per billion.
**Figure 1: FeNO response to BRJ and PL**

Abbeviations:
BRJ = nitrate-rich; PL = placebo, nitrate-depleted beetroot juice.